Keyphrases
Patients with Advanced Cancer
100%
Cancer of Unknown Primary
100%
Non-randomized Clinical Trial
100%
Pembrolizumab
100%
Progression Rate
57%
Non-progression
57%
Patients with Cancer
42%
Tumor-infiltrating Lymphocytes
42%
Programmed Death-ligand 1 (PD-L1)
42%
Immune-related
42%
Overall Survival
28%
Response Evaluation Criteria in Solid Tumors (RECIST)
28%
Duration of Response
28%
Objective Response Rate
28%
Systemic Therapy
14%
Rare Malignancy
14%
Rare Tumors
14%
In Cancer
14%
Clinical Activity
14%
Partial Response
14%
Progression-free Survival
14%
Median Progression-free Survival
14%
Performance Status
14%
Measurable Disease
14%
Poorly Differentiated Carcinoma
14%
Treatment-related Adverse Events
14%
Safety Profile
14%
Adult Patients
14%
Pretreatment Biopsy
14%
Trial Registration
14%
Lymphocyte Infiltration
14%
Line of Therapy
14%
Two-line
14%
Acceptable Safety
14%
Biomarkers of Response
14%
Treatment Discontinuation
14%
Acute Kidney Injury
14%
Limited Treatment Options
14%
Immune Checkpoint Inhibitors
14%
Basket Trial
14%
PD-1 Inhibitor
14%
Medicine and Dentistry
Randomized Clinical Trial
100%
Advanced Cancer
100%
Cancer of Unknown Primary Origin
100%
Pembrolizumab
100%
Programmed Cell Death
57%
Tumor Infiltrating Lymphocyte
42%
Immunity
42%
Overall Survival
28%
Progression Free Survival
28%
Biological Marker
14%
Cancer
14%
Diseases
14%
Systemic Therapy
14%
Biopsy Technique
14%
Rare Tumor
14%
Response Evaluation Criteria in Solid Tumors
14%
Adverse Event
14%
Carcinoma
14%
Lymphocytic Infiltration
14%
Acute Kidney Injury
14%
Immune Checkpoint Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Randomized Clinical Trial
100%
Cancer of Unknown Primary Site
100%
Pembrolizumab
100%
Neoplasm
57%
Programmed Cell Death
57%
Overall Survival
28%
Progression Free Survival
28%
Diseases
14%
Solid Malignant Neoplasm
14%
Adverse Event
14%
Biological Marker
14%
Carcinoma
14%
Lymphocytic Infiltration
14%
Acute Kidney Failure
14%
Immune Checkpoint Inhibitor
14%